BioSpace News Archive

Immunic, Inc. announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present previously unpublished data regarding the company’s lead program, IMU-838, at the GI Inflammatory Diseases Summit in Boston.

Mallinckrodt plc, confirmed it has achieved 50 percent patient enrollment in the company’s Phase 2B study designed to assess the efficacy and safety of Acthar® Gel as an investigational treatment for amyotrophic lateral sclerosis.

Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced the use of its pharmaceutical-grade L-glutamine in a clinical study to determine its efficacy in lowering blood sugar in patients with type II diabetes.

At Metabolomics 2019, Bruker highlights innovative mass spectrometry and Nuclear Magnetic Resonance systems and novel high-value solutions for molecular phenomics and clinical metabolomics research.

Correvio Pharma Corp. announced it has resubmitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for Brinavess™, its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation.

Tetraphase Pharmaceuticals, Inc. announced the presentation of new data on XERAVA™, a novel, fully synthetic fluorocycline approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of complicated intra-abdominal infections in adults, and TP-6076, a clinical-stage candidate targeting multidrug-resistant infections, at the American Society for Microbiology Microbe 2019 Annual Meeting held June 20-24 in San Francisco.

Social media and news aggregation site will highlight real-time digital conversations at DIA 2019

Veeva delivers a modern cloud application for the management of adverse events

Bristol-Myers Squibb Company announced topline results from CheckMate -459, a randomized Phase 3 study evaluating Opdivo versus sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma.

Technavio’s latest market research report on the global thoracic surgery market predicts the market to witness a CAGR of over 9% during the forecast period.